Hagerty, Inc. (NYSE:HGTY) director Robert I. Kauffman has sold a total of 14,253 shares of the company’s Class A Common Stock in a series of transactions, according to a recent SEC filing. The sales, which occurred between September 26 and September 30, amounted to nearly $148,000. The transactions were executed under a Rule 10b5-1 trading plan, which Kauffman had adopted on August 11, 2023. This plan allows insiders to set up a predetermined schedule to sell stocks at a time when they are not in possession of material non-public information, providing a defense against accusations of insider trading. The sales…
Author: user
Bitcoin.Nurphoto | Getty ImagesBitcoin and crypto stocks retreated on the final trading day of September, following a rally last week, but the cryptocurrency still posted its second winning September in a row.The price of bitcoin was last lower by 3.7% at $63,451.12, after briefly reclaiming the $65,000 level last week, according to Coin Metrics. In crypto stocks, Coinbase slid 6.8% and MicroStrategy fell 4.3%.For the month, bitcoin finished its strongest September ever with an 7.9% gain and its second positive September — historically the cryptocurrency’s weakest month — in a row. It posted a quarterly gain of 2.8%.Coinbase finished the…
Friday’s monthly jobs report, along with a slew of other economic data slated for release this week, is likely to drive the stock market even higher if it surprises to the upside.That’s because any evidence that the Federal Reserve is cutting interest rates amid an ideal backdrop of continuous economic growth, a solid labor market, and easing inflation would be a “hugely bullish” outcome for equities, Citi head of US equity trading strategy Stuart Kaiser said.”Everything is about the growth side of the economy, and everything is about the consumer,” Kaiser told Yahoo Finance. “Any data that suggests consumer spending is…
On Monday, Oppenheimer maintained its Outperform rating and $15.00 price target on Savara (NASDAQ:), a pharmaceutical company focused on rare respiratory diseases. The firm’s confidence in the stock is bolstered by the commercial potential of Savara’s Molbreevi for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung condition currently without any approved pharmacological treatments. Molbreevi’s Phase 3 IMPALA-2 trial results have strengthened the optimism surrounding its prospects. The trial demonstrated a statistically significant improvement in lung function, specifically a 6% increase in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) at Week 24 and a sustained 6.9%…
Image source: Getty Images Nvidia (NASDAQ: NVDA) stock has been creeping back up recently. From a low of $102 on 6 September, it’s jumped 18% to reach $121. For longer-term investors though, such changes are merely rounding errors. Nvidia shares are up more than 262 times in value since September 2014! Here, I want to look at analysts’ growth forecasts through to 2026 to determine if I think the stock looks attractively priced at $121. Revenue growth estimates Nvidia’s fiscal year runs from February to January. Somewhat confusingly, this means that the current year is FY25 and the next one…
On Monday, TD Cowen reaffirmed its Buy rating on shares of Humacyte (NASDAQ:HUMA) with a consistent price target of $10.00. This confirmation follows a recent call hosted by Humacyte with three vascular surgeons experienced in using the company’s ATEV (Artificial Tissue Engineered Vessel) in complex cases under expanded access. During the call, the surgeons shared insights into their use of ATEV, providing evidence that supports the clinical value of Humacyte’s technology. Their experiences suggest potential for strong early commercial adoption of ATEV, contingent on receiving FDA approval. The feedback from these key opinion leaders (KOLs) has reinforced TD Cowen’s positive…
Image source: Rolls-Royce plc It has been an incredible year for the Rolls-Royce (LSE: RR.) share price. In the last 12 months, it has risen by a staggering 140.9%. But with the stock now sitting at £5.22, what’s next for the FTSE 100 stalwart? It seems like Rolls is unable to slow down at the moment. But surely its share price can’t just keep rising? Exciting times ahead? Well, to answer that, it’s worth looking at what has boosted the stock in recent times. The latest reason is that Rolls was chosen by CEZ Group, the Czech state utility company,…
Stellantis stock (STLA) tumbled 13% early Monday after the company issued a stark warning about its North American operations, dragging other auto stocks lower in sympathy.Stellantis — which counts Dodge, Ram, and Jeep vehicles in its product portfolio — said it would have to “enlarge remediation actions” it was planning to take due to performance issues in North America and “deterioration” in the global market, in particular, China.“Actions include North American shipment declines of more than 200,000 vehicles in the second half of 2024 (up from 100,000 prior guidance), compared to the prior year period, increased incentives on 2024 and…
In a recent transaction, George J. Christ, a significant shareholder in Altair Engineering Inc. (NASDAQ:ALTR), sold 50,048 shares of the company’s stock. The sale was executed at an average price of $95.07 per share, resulting in a total value of approximately $4.76 million. The transactions occurred in multiple parts, with share prices ranging from $94.95 to $95.9375. This information was disclosed in compliance with regulatory requirements, and full details of the shares sold at each price point are available upon request. Following the sale, Christ still holds a substantial number of shares indirectly through various trusts and investment entities. Specifically,…
Image source: Getty Images Having performed awfully for investors in recent years, Diageo (LSE: DGE) shares have climbed nearly 7% in the last month, thrashing the FTSE 100 index as a whole (down 1%). Is the beginning of an almighty recovery in a stock I’ve long fancied owning? Well, last week’s trading commentary, released ahead of its Annual General Meeting certainly seems to have pushed some to take a fresh look at the company. Primed to recover? On 26 September, CEO Debra Crew said that the premium spirit maker’s expectations on trading hadn’t changed since it released full-year earnings back…